Automated purification of high-quality genomic DNA
09 October, 2014 by Eppendorf South Pacific Pty LtdThe Eppendorf epMotion M5073 with MagSep Tissue gDNA kit is an efficient and effective way of isolating genomic DNA in an automated environment.
Genera teams up with Beckman Coulter, taps new CEO
03 October, 2014 by Dylan Bushell-EmblingGenera Biosystems has announced a business collaboration with Beckman Coulter Lifesciences for molecular diagnostics assays and promoted director Richard Hannebery to the post of CEO.
Genetic Technologies launches BrevaGenplus
02 October, 2014 by Dylan Bushell-EmblingGenetic Technologies has launched the enhanced version of its breast cancer risk test and appointed two new non-executive directors to help with its restructuring.
GTG selling Australian genetics business
23 September, 2014 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) will sell its Australian genetics testing business to a Primary Health Care subsidiary for $2m.
GTG restructures to focus on molecular diagnosis
16 September, 2014 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has announced a restructuring project, as well as plans to launch the upgraded version of breast cancer risk test BREVAGen next month.
MicroRNA profiling
15 September, 2014 by Merck Pty LimitedAs microRNA (miRNA)-based research shifts from discovery of new miRNAs to elucidating their biological roles and their utility as biomarkers, robust methods are needed to profile large sample cohorts.
Coffee genome sequenced
09 September, 2014An international research effort into the genome sequencing of the coffee plant has revealed its 'convergent evolution' with unrelated cacao and tea plants.
Federal court upholds decision on Myriad patent
05 September, 2014The Federal Court of Australia has upheld its decision from last year in favour of Myriad Genetics patenting isolated DNA associated with breast cancer gene mutations.
Telomeres tell on cancer cells
26 August, 2014Different DNA sequences in the telomeres of cancer cells may help unravel how these cells maintain their ability to endlessly multiply.
Garvan and Roche to collaborate on epigenomic analysis
25 August, 2014Roche Sequencing and the Garvan Institute of Medical Research have announced a collaboration to develop new technologies for targeted epigenomic analysis using DNA sequencing.
New EMBL Australia node
21 August, 2014A partnership between the University of New South Wales and the European Molecular Biology Laboratory will set up a new EMBL Australia node.
Abcam establishes a direct service for ANZ
20 August, 2014Protein research tool provider Abcam has established a direct service to Australia and New Zealand.
Personalised, predictive, preventive and participatory
20 August, 2014The upcoming Annual Scientific Conference of the Australasian Association of Clinical Biochemists (AACB) will focus on Clinical Biochemistry Supporting P4 Medicine - the four 'Ps' representing personalised, predictive, preventive and participatory.
Finding markers for inflammation and auto-immunity
06 August, 2014 by Graeme O'NeillProfessor Mark Hogarth has spent most of his career studying the role of Fc receptors in inflammatory and auto-immune disorders. Found on the surface of a variety of immune cells, these antibody-binding receptors are now prospective targets for new treatments of inflammation, therapeutic monoclonal antibodies in cancer and manipulation in vaccines for HIV-AIDS.
QFAB, Garvan team for genome sequence analysis
04 August, 2014 by Dylan Bushell-EmblingQFAB Bioinformatics and the Garvan Institute of Medical Research will combine their capabilities to offer human genome sequence data analysis for scientists and clinicians.
